Argentus Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Argentus Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,318	Closed	-$197K	–	673
2016 Q1	$197K	Sell	2,318 -37	-2%	-$3.35K	0.07%	316
2015 Q4	$296K	Sell	2,355 -7,962	-77%	-$961K	0.09%	203
2015 Q3	$1.07M	Buy	+10,317	New	+$1.33M	0.16%	166
2015 Q2	–	Sell	-13,721	Closed	-$1.62M	–	346
2015 Q1	$1.62M	Sell	13,721 -380	-3%	-$45.5K	0.26%	102
2014 Q4	$1.68M	Buy	+14,101	New	+$1.59M	0.28%	103

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Argentus Capital Management's VRTX Position: Q2 2016 in Review

Argentus Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 2,318 shares — an estimated $197K sold.

Argentus Capital Management first reported a position in VRTX in Q4 2014 and held it in 5 quarters. The position peaked at $1.68M in Q4 2014. 482 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

Argentus Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Argentus Capital Management sold 2,318 Vertex Pharmaceuticals shares in Q2 2016, an estimated $197K.
Argentus Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Argentus Capital Management's Vertex Pharmaceuticals position peaked at $1.68M in Q4 2014.
482 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Argentus Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.